(Q40943607)

25 September 2017

1 reference

title

Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma (English)

1 reference

25 September 2017

3

1 reference

25 September 2017

Audisio RA

1

1 reference

25 September 2017

Veronesi P

2

1 reference

25 September 2017

Chiappa A

4

1 reference

25 September 2017

Andreoni B

5

1 reference

25 September 2017

Bombardieri E

6

1 reference

25 September 2017

Geraghty JG

7

1 reference

25 September 2017

publication date

1 April 1996

1 reference

25 September 2017

1 reference

25 September 2017

volume

5

1 reference

25 September 2017

issue

2

1 reference

25 September 2017

page(s)

49-63

1 reference

Cancer mortality in Italy, 1990

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

The radiologic diagnosis of pancreatic cancer. The effect of new imaging techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Preoperative staging and assessment of resectability of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Cancer of the pancreas. Diagnostic accuracy and survival statistics

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Pancreatic cancer in 1988. Possibilities and probabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Pancreas cancer — duct cell adenocarcinoma: Survival in relation to site, size, stage and type of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Usefulness of serial serum carcinoembryonic antigen (CEA) determinations during anticancer therapy or long-term follow-up of gastrointestinal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Ultrasonography and tumor-associated antigens. The concept of combining noninvasive tests in the screening for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Serum and pancreatic juice carcinoembryonic antigen in pancreatic and biliary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Selectivity of the micro-leukocyte adherence inhibition assay in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Circulating carcinoembryonic antigen in pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

[CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon]

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Carcinoembryonic antigen assay in cancer of the colon and pancreas and other digestive tract disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

A cancer-associated galactosyltransferase isoenzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Sensitive serum markers for detecting pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Factors controlling the circulating CEA levels in pancreatic cancer: some clinical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Free and bound carcinoembryonic antigen in neoplasms and in normal adult and fetal tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Noninvasive Diagnosis of Advanced Pancreatic Cancer by Real-Time Ultrasonography, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Prospective Evaluation of the Diagnostic Efficacy of CA 19–9 Assay as a Marker for Gastrointestinal Cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Specific Antigen in Serum of Patients with Colon Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the nci serum bank

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Evaluation of a new tumor-associated antigen in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

[Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer]

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

[Diagnosis of recurrence and evaluation of the course of pancreatic cancer. Combined use of sonography and the new tumor marker CA 19-9]

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

[Clinical significance of the circulating tumor-associated antigen CA 19-9 in cancers of the digestive tract]

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Small carcinoma of the pancreas. Clinical and pathologic evaluation of 17 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

CA 19-9 and pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Determination and significance of a new carbohydrate antigen CA19-9 in digestive system cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Monoclonal antibody defines CA 19-9 in pancreatic juices and sera

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Value of ultrasonographic examination combined with measurement of serum tumor markers in the diagnosis of pancreatic cancer of less than 3 cm in diameter

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

CA 494--a new tumor marker for the diagnosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Elevated serum levels of tumor marker CA19-9 in acute cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

CA 242 is a new tumor marker for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Colorectal carcinoma antigens detected by hybridoma antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Tumour-associated and differentiation antigens on the carbohydrate moieties of mucin-type glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Serum levels of cancer-associated antigen CA-195 in gastrointestinal cancers and its comparison with CA19-9.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Comparison of serological expression of different epitopes on the CA50-carrying antigen CanAg

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

The detection of human pancreatic cancer-associated antigen in the serum of cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Carcinoma of the Pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Purification and characterization of two human pancreatic elastases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Serum elastase I levels in pancreatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Diagnostic value of serum elastase 1 in pancreatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Serum elastase 1 in chronic pancreatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Serum immunoreactive elastase in diagnosis of pancreatic diseases. A sensitive marker for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Values of serum carcinoembryonic antigen and elastase 1 in diagnosis of pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

New oncofetal antigen for human pancreas.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Studies on an oncofetal antigen, POA

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Immunologic studies on a pancreatic oncofetal protein

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Isolation, characterization and clinical evaluation of a pancreas cancer-associated antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Leukocyte adherence inhibition: a simple test for cell-mediated tumour immunity and serum blocking factors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Reactivity of a monoclonal antibody with human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Plasma trypsin in chronic pancreatitis and pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Clinical value of serum immunoreactive trypsin concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Pancreatic Cancer: A Continuing Diagnostic Dilemma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Demographic characteristics of cancer of the pancreas: mortality, incidence, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

The pancreatic cancer problem

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Novel tumour markers: a diagnostic role in pancreatic cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Clinical usefulness of computer-assisted diagnosis using combination assay of tumor markers for pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Tissue expression of the tumor marker CA 50 in benign and malignant pancreatic lesions. A comparison with CA 19-9.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Concentration and localization of carbohydrate antigen 19-9 in tissues of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

CA 19-9 as a prognostic index after resection for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Diabetes and the Risk of Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Cigarette smoking and cancer of the pancreas: evidence from a population-based case-control study in Toronto, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: a prospective study in multiinstitutions

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2896%2980001-6

7 January 2021

10.1016/S0960-7404(96)80001-6

Identifiers

DOI

0 references

1 reference